Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status

@article{Madhi2017VaccinationW1,
  title={Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status},
  author={Shabir Ahmed Madhi and Anthonet L. Koen and Lisa Jose and Nadia van Niekerk and Peter V. Adrian and Clare L. Cutland and Nancy A. François and Javier Ruiz-Gui{\~n}az{\'u} and Juan Pablo Yarz{\'a}bal and Marta Moreira and Dorota Borys and Lode M Schuerman},
  journal={Medicine},
  year={2017},
  volume={96}
}
Background: Phase III, open-label, single-center, controlled study in South Africa (ClinicalTrials.gov: NCT00829010) to evaluate immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) children. Methods: Children stratified by HIV status received PHiD-CV primary vaccination (age 6/10/14… 

Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children

While ART and pneumococcal conjugate vaccines (PCV) have reduced IPD morbidity and mortality in HIV-infected children, ART-naïve and immunosuppressed children have inferior immunogenicity to most PCV serotypes; highlighting the need for concomitant use of ART with PCV.

Decreased diarrheal and respiratory disease in HIV exposed uninfected children following vaccination with rotavirus and pneumococcal conjugate vaccines

Significant declines in the burden of diarrheal and respiratory illness were observed among HEU children in Botswana following the introduction of RV and PCV, and these vaccines may maximally benefit HEUChildren in rural areas with higher disease burden.

Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials

This analysis of two concurrent clinical trials did not reveal differences in bacterial NPC prevalence or acquisition in PCV7- and PHiD-CV-vaccinated children.

Effect of Maternal Vaccination on the Immunogenicity of PCV-10 in HIV-exposed Uninfected Infants: A Randomized Study of PCV-10, PPV-23 or Placebo Administered during Pregnancy.

This study addressed secondary objectives of a double-blind, placebo-controlled, randomized trial of the safety, immunogenicity and transplacental transport of maternal antibodies after PNC vaccination of pregnant women with HIV, finding that maternal antibody levels in infants up to 8 weeks of life were higher than expected.

Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial

Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) and human rotavirus vaccine (HRV) when co-administered with RTS,S/AS01 in African infants had an acceptable safety profile.

Ten years of experience with the pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (Synflorix) in children

This review highlights that Synflorix vaccination has reduced the pneumococcal disease burden in young children in the last 10 years and continuous efforts are needed to improve access to pneumitiscal conjugate vaccines by increasing vaccination coverage in countries with ongoing pneumococal immunization programs.

References

SHOWING 1-10 OF 35 REFERENCES

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Vaccination with a 9-valent pneumococcal conjugate vaccine reduced the incidence of radiologically confirmed pneumonia among children with and those without HIV infection.

Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection

Children with paHIV mount a robust serological response to PCV13 for most but not all vaccine serotypes, and Viral load suppression with HAART and higher baseline IgG concentration are associated with higher postvaccination antibody levels.

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

In sub-Saharan African infants, PHiD-CV was immunogenic for all vaccine pneumococcal serotypes and protein D, and vaccine tolerability was generally comparable between the PHid-CV and control groups.

Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.

Results suggest PHiD-CV can be co-administered with other vaccines included in the National Programme on Immunisation, and immunogenicity, reactogenicity and safety of the 10- valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine were evaluated in Nigeria.

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children

A booster dose of PHiD-CV was well tolerated when administered to Malian children in the second year of life and was highly immunogenic for all 10 vaccine pneumococcal serotypes and NTHi protein D.

Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants.

Serotype-specific antibody concentration and opsonophagocytic activity (OPA) were evaluated after 3 doses of pneumococcal conjugate vaccine in HIV-noninfected infants born to HIV-seronegative or HIV-positive mothers and M-/I- infants had superior OPA responses, compared with those in HIV+/ART+ infants.

Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants.

Among South African infants, antenatal HIV exposure was associated with lower specific antibody responses in exposed uninfected infants compared with unexposed infants at birth, but with robust responses following routine vaccination.